5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
This study is ongoing, but not recruiting participants.
PD Dr. med. Volker Heinemann
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
PD Dr. med. Volker Heinemann, Ludwig-Maximilians - University of Munich
First received: February 9, 2007
Last updated: October 22, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||December 2016|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|